Lung Cancer Trial, Not Yet Recruiting NCT07287904 Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT07287904
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 to 80 years old who have undergone surgery to fully remove lung cancer (known as a complete or R0 resection).
  • People whose cancer was confirmed after surgery to be at stage IB, II, or IIIA, and whose cancer type was confirmed by laboratory testing to be adenocarcinoma (a specific type of lung cancer).
  • People whose cancer has tested positive for a specific gene change called an EGFR mutation, specifically the type known as 19del or L858R.
  • People who have received a type of targeted drug treatment after surgery called an EGFR-TKI (a medication that targets the EGFR gene mutation).
  • People who have complete and clearly documented scans from before surgery, along with genetic testing results and pathology (laboratory) reports.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose cancer tested negative for the EGFR gene mutation.
  • People whose surgery did not fully remove the cancer (referred to medically as R1 or R2 resection).
  • People who did not receive EGFR-TKI targeted drug treatment after their surgery.
  • People whose cancer has come back or has reached an advanced stage.
  • People whose medical records from before or after surgery are incomplete.
  • People who passed away within 30 days of having surgery.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 24 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiaorong Dong, Dr, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phone: 02785726114

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Registry
ClinicalTrials.gov
Start date
25 December 2025
Est. completion
1 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

DFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov